6 stories from 4 sources
Supporting Articles
Clinical trials are starting for several experimental Ebola treatments that showed promise in earlier research. Researchers aim to test them during the active outbreak to determine which drugs reduce deaths and can be deployed at scale.
3:11 PMThe New York TimesA sick newborn brought to an orphanage in eastern Democratic Republic of Congo triggered an Ebola outbreak that spread among highly vulnerable children. Authorities are monitoring the home, but at least two infants have died.
12:30 PMThe New York TimesA large study found that people who moved from smoking cigarettes to using electronic cigarettes had higher lung cancer risk than people who quit smoking entirely. The results suggest vaping may not eliminate cancer risk for former smokers even if it reduces exposure to some cigarette toxins.
8:00 PMNatureGSK agreed to buy a biotech company for $10.6bn, its largest biotech acquisition in more than 25 years. The deal is positioned as a major push to expand GSK's cancer portfolio and future growth drivers.
12:00 AMFinancial TimesSummary
Clinical trials are starting for several experimental Ebola treatments that showed promise in earlier research. Researchers aim to test them during the active outbreak to determine which drugs reduce deaths and can be deployed at scale.
Why it matters
Proven treatments could rapidly lower deaths and strengthen outbreak control by making people more willing to seek care.
Summary
A sick newborn brought to an orphanage in eastern Democratic Republic of Congo triggered an Ebola outbreak that spread among highly vulnerable children. Authorities are monitoring the home, but at least two infants have died.
Why it matters
An Ebola cluster among infants in institutional care can turn a small exposure into a fast-moving outbreak with high fatality risk and broader community spread.
Summary
A large study found that people who moved from smoking cigarettes to using electronic cigarettes had higher lung cancer risk than people who quit smoking entirely. The results suggest vaping may not eliminate cancer risk for former smokers even if it reduces exposure to some cigarette toxins.
Why it matters
If vaping is less protective than quitting, public health messaging and regulation will shift toward complete nicotine cessation rather than substitution.
Summary
GSK agreed to buy a biotech company for $10.6bn, its largest biotech acquisition in more than 25 years. The deal is positioned as a major push to expand GSK's cancer portfolio and future growth drivers.
Why it matters
A $10.6bn oncology acquisition resets expectations for GSK's growth plan and can tighten the M&A market for cancer assets across pharma.
A curated list of other prominent stories from this day.
The FDA approved a Sanofi diabetes drug for use in children with stage 3 diabetes. The decision follows an earlier internal dispute in which career reviewers and the political appointee leading CDER clashed over the drug’s regulatory path.
9:22 AMStat NewsDawn Zuidgeest-Craft describes entering medical residency at nearly 73 after pursuing medicine later in life, arguing that age does not preclude clinical contribution. She frames her decision as a serious commitment to patient care and notes that some physicians practice into very old age.
4:30 AMStat NewsSummary
The FDA approved a Sanofi diabetes drug for use in children with stage 3 diabetes. The decision follows an earlier internal dispute in which career reviewers and the political appointee leading CDER clashed over the drug’s regulatory path.
Why it matters
It signals how the FDA may resolve contested approvals and expands treatment access for children with severe diabetes.
Summary
Dawn Zuidgeest-Craft describes entering medical residency at nearly 73 after pursuing medicine later in life, arguing that age does not preclude clinical contribution. She frames her decision as a serious commitment to patient care and notes that some physicians practice into very old age.
Why it matters
The story tests whether a workforce under strain can widen entry pathways while keeping patient safety, training rigor, and program economics intact.
Make it yours
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!